Related Experiment Video

Updated: Jul 17, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

The Anti-Mullerian hormone and ovarian cancer

Antonio La Marca1, Annibale Volpe

  • 1Mother-Infant Department, Institute of Obstetrics and Gynecology, University of Modena and Reggio Emilia, Modena, Italy. antlamarca@libero.it

Human Reproduction Update
|January 11, 2007
PubMed

Insights

Anti-Mullerian hormone (AMH) plays a role in male development and ovarian function. AMH shows promise as a diagnostic marker for granulosa cell tumors and a potential therapeutic agent for ovarian cancer.

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Oncology

Background:

  • Anti-Mullerian hormone (AMH) is crucial for male sex differentiation by inducing Mullerian duct regression.
  • AMH is also secreted by ovarian granulosa cells, suggesting a role in ovarian folliculogenesis.

Purpose of the Study:

  • To explore the significance of AMH as a diagnostic marker and potential therapeutic agent for ovarian cancer.
  • To review current findings on AMH's role in granulosa cell tumors (GCT) and its potential in ovarian cancer treatment.

Main Methods:

  • Literature review of studies investigating AMH's role in reproductive development and ovarian cancer.
  • Analysis of diagnostic performance of AMH as a biomarker for GCT.
  • Evaluation of in vitro and in vivo studies on AMH's anti-cancer effects.

Main Results:

  • AMH is a specific circulating marker for GCT with high diagnostic sensitivity (76-93%).
  • Post-operative AMH levels can monitor treatment efficacy and detect recurrence in GCT patients.
  • AMH demonstrates inhibitory effects on epithelial ovarian cancer cells in vitro and in vivo.

Conclusions:

  • AMH is a valuable diagnostic and prognostic marker for granulosa cell tumors.
  • AMH's inhibitory action on ovarian cancer cells suggests potential as an adjuvant or neoadjuvant therapy.
  • Further research is warranted to establish the clinical utility of AMH in ovarian cancer management.

More Related Videos

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...